Charles Williams
Fortune : 473 250 $ au 30/06/2026
Fortune : 473 250 $ au 30/06/2026
Charles Williams is Secretary & Chief Operating Officer at Surrozen, Inc. since 2025.
Formerly, Mr. Williams was Head-Corporate Development at Jazz Pharmaceuticals Plc from 2013 to 2020 and Director-Corporate & Business Development at MAP Pharmaceuticals LLC from 2008 to 2013.
Mr. Williams completed undergraduate education at Cornell University.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SURROZEN INC 0,16% | 15/06/2026 | 18 237 ( 0,16% ) | 473 250 $ | 30/06/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| SURROZEN, INC. | Directeur des opérations | 01/02/2024 |
| Sociétés | Poste | Fin |
|---|---|---|
| JAZZ PHARMACEUTICALS PLC | Corporate Officer/Principal | 01/11/2020 |
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology Develops therapies and inhalation delivery technologies | Corporate Officer/Principal | 01/01/2013 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology Develops therapies and inhalation delivery technologies | Health Technology |
Cornell University
Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Jazz Pharmaceuticals Plc
Jazz Pharmaceuticals Plc Pharmaceuticals: MajorHealth Technology Engages in the development and commercialization of pharmaceutical products to treat neurological disorders | Health Technology |
Surrozen, Inc.
Surrozen, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that discovering and developing drug candidates | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national